Excelra, HotSpot Therapeutics partner on drug discovery

By The Science Advisory Board staff writers

May 26, 2022 -- Excelra is partnering with HotSpot Therapeutics to further the discovery and development of small molecule therapy candidates directed toward allosteric targets that have been difficult to treat, or untreatable, with traditional small molecule approaches.

HotSpot Therapeutics will use data from Excelra's flagship product Global Online Structure Activity Relationship (GOSTAR) database with its machine learning and artificial intelligence models to accelerate both hit identification and chemical diversification in the field of allostery, according to Excelra.

If you like this content, please share it with a colleague!

Related Reading

Excelra partners with XtalPi
Excelra has partnered its Global Online Structure Activity Relationship Database with XtalPi, an artificial intelligence-based pharmaceutical biotechnology...

Silexon partners with Excelra for AI-driven drug discovery research
Silexon is partnering with Excelra, deploying Excelera's global online structure activity relationship database to strengthen its artificial intelligence...

HotSpot Therapeutics secures $100M to advance allosteric platform
HotSpot Therapeutics has closed a $100 million series C financing round to advance its allosteric drug discovery platform to the clinic. This brings...

Excelra launches updated Gostar chemistry insights engine
Data science firm Excelra has released an updated version of its Gostar chemistry insights engine. The updated version includes a more advanced search...